| Code | CSB-RA004937MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to IBI-355, targeting CD40LG (CD40 ligand, also known as CD154). CD40LG is a type II transmembrane protein primarily expressed on activated T cells that plays a crucial role in adaptive immunity by binding to CD40 on antigen-presenting cells. This interaction is essential for T cell-dependent B cell activation, immunoglobulin class switching, germinal center formation, and the generation of memory B cells. Dysregulation of CD40-CD40LG signaling has been implicated in various autoimmune and inflammatory conditions, including systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, and transplant rejection.
IBI-355 is a therapeutic antibody designed to block CD40-CD40LG interactions, thereby modulating immune responses in autoimmune disorders. This biosimilar antibody serves as a valuable research tool for investigating CD40LG-mediated immune mechanisms, studying T cell-B cell interactions, exploring therapeutic intervention strategies in autoimmune diseases, and evaluating immune checkpoint pathways. It enables researchers to examine the molecular basis of adaptive immunity and inflammatory processes in various experimental models.
There are currently no reviews for this product.